Status:

COMPLETED

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Lead Sponsor:

Incyte Corporation

Conditions:

Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) pr...

Eligibility Criteria

Inclusion

  • Men and women, aged 18 years or older.
  • Documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.
  • Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

Exclusion

  • History of central nervous system lymphoma (either primary or metastatic).
  • Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan PI3K inhibitor.
  • Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.
  • Active graft-versus-host disease.
  • Liver disease: Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).

Key Trial Info

Start Date :

November 20 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 30 2024

Estimated Enrollment :

162 Patients enrolled

Trial Details

Trial ID

NCT03235544

Start Date

November 20 2017

End Date

April 30 2024

Last Update

March 18 2025

Active Locations (103)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 26 (103 locations)

1

University of Alabama At Birmingham Comprehensive Cancer Center

Birmingham, Alabama, United States, 35205

2

St. Joseph Heritage Healthcare

Santa Rosa, California, United States, 95403

3

Rocky Mountain Cancer Center-Aurora

Aurora, Colorado, United States, 80012

4

Asclepes Research Centers

Brooksville, Florida, United States, 34613